Vaccination of premature newborns
https://doi.org/10.22625/2072-6732-2023-15-4-25-34
Abstract
Premature newborns are most vulnerable to the severe infectious diseases. The timeliness of vaccination in this group of children is extremely important. Historically, however, vaccination coverage for premature newborns has been significantly reduced due to unjustified contraindications. This is due to the fear of developing post-vaccination complications and the opinion that the immune response to vaccines in preterm newborns is reduced. In addition, in our country, there are no approved federal clinical guidelines for the vaccination of premature newborns, which determines the lack of a unified approach among medical workers and raises doubts among parents.
The article presents a review of Russian and foreign literature data, highlighting the state of the problem of timeliness and completeness of vaccination coverage of premature newborns. Features of the immunity of a child born prematurely and the possibility of an adequate response to vaccine antigens in various degrees of prematurity. According to the list of the National Immunization Schedule, scientific and practical data on the safety and efficacy of vaccines registered in Russia, the benefits of complying with approved schedule and the positive non-specific effects of individual vaccines are given. Data on the specific prevention of RS-virus infection are presented. It has been shown that conditions that can develop after vaccination and are characteristic of prematurity are not directly related to the vaccine and that premature newborns is able to develop a sufficient immune response. Accordingly, children born prematurely should be immunized in accordance with the passport age with the stabilization of the child’s condition and adequate weight gain.
About the Authors
A. A. Ruleva
Pediatric Research and Clinical Center for Infectious Diseases
Russian Federation
Russian Federation
Saint-Petersburg
S. M. Kharit
Pediatric Research and Clinical Center for Infectious Diseases;
Saint-Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Saint-Petersburg
References
1. Fortmann M.I., Dirks J., Goedicke-Fritz S., at al. Immunization of preterm infants: current evidence and future strategies to individualized approaches. Semin Immunopathol. 2022; 44(6): 767-784. http://dx.doi.org/10.1007/s00281-022-00957
2. World Health Organization. https://www.who.int/news/item/09-05-2023-152-million-babies-born-preterm-in-the-lastdecade
3. World Health Organization . WHA global nutrition targets 2025: low birth weight policy brief. https://media.tghn.org/articles/WHO_NMH_NHD_14.5_eng.pdf
4. Harit S.M., Kaplina S.P., Ruleva A.A. i dr. Nedonoshennye deti: bezopasnost’ vakcinacii i specificheskij immunnyj otvet. Jepidemiologija i vakcinoprofilaktika. 2015; 14, № 4 (83): S. 61-66
5. Langkamp D.L., Davis J.P. Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight children. J Pediatr. 1996; 128 (5):654-9. http://dx.doi.org/10.1016/s0022-3476(96)80131-4
6. Marshall H., Clarke M., Rasiah K., at al. Predictors of disease severity in children hospitalized for pertussis during an epidemic. Pediatr Infect Dis J. 2015; 34(4): 339-45. http://dx.doi.org/10.1097/INF.0000000000000577
7. Anderson J., Anh Ha Do L., Wurzel D. et al. Severe respiratory syncytial virus disease in preterm infants: a case of innate immaturity. Thorax 2021; 76: 942-950 http://dx.doi.org/10.1136/thoraxjnl-2020-216291
8. Sisson H. Gardiner E., Watson R. Vaccination timeliness in preterm infants: An integrative review of the literature. J Clin Nurs. 2017; 26(23-24): 4094-4104. http://dx.doi.org/10.1111/jocn.13916
9. Bonhoeffer J., Siegrist C.A., Heath P.T. Immunisation of premature infants. Arch Dis Child 2006; 91(11): 929e35. https://doi.org/10.1136/adc.2005.086306
10. Collins A., Weitkamp J.H., Wynn J.L. Why are preterm newborns at increased risk of infection? Arch Dis Child Fetal Neonatal Ed. 2018; 103(4): 391-394. http://dx.doi.org/10.1136/archdischild-2017-313595
11. Ballard O., Morrow A.L. Human milk composition: nutrients and bioactive factors. Pediatr. Clin. North. Am. 2013; 60(1): 49-74. http://dx.doi.org/10.1016/j.pcl.2012.10.002
12. Safina A.I., Voljanjuk E.V., Potapova M.V. i dr. Sostojanie zdorov’ja detei, rodivshihsja nedonoshennymi: po dannym gorodskogo centra katamneza g. Kazani. Ros vestn perinatol i pediatr 2018; 63:(5): 192–196. http://dx.doi.org/10.21508/1027–4065–2018–63–5–192–196
13. Saroha M., Faridi M.M., Batra P., at al. Immunogenicity and safety of early vs delayed BCG vaccination in moderately preterm (31-33 weeks) infants. Hum Vaccin Immunother. 2015; 11(12): 2864-71 http://dx.doi.org/10.1080/21645515.2015.1074361
14. Negrete-Esqueda, L., & Vargas-Origel, A. (2007). Response to Bacillus Calmette-Guérin Vaccine in Full-Term and Preterm Infants. American Journal of Perinatology. 24 (3), 183–189 http://dx.doi.org/10.1055/s-2007-970080
15. Berkley J.A. Safety and Immunogenicity of Early Bacillus Calmette-Guérin Vaccination in Infants. Who Are Preterm and/or Have Low Birth Weights: A Systematic Review and Meta-analysis. JAMA Pediatr. 2019; 173(1): 75-85 http://dx.doi.org/10.1001/jamapediatrics.2018.4038
16. Scheid A., Borriello F., Pietrasanta C., at al. Adjuvant Effect of Bacille Calmette-Guérin on Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn. Front Immunol. 2018; 9: 29. http://dx.doi.org/10.3389/fimmu.2018.00029
17. Aaby P., Roth A., Ravn H,et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011; 204: 245 http://dx.doi.org/10.1093/infdis/jir240
18. Freitas da Motta M.S., Mussi-Pinhata M.M., Jorge S.M., at al. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine. 2002; 20(11-12): 1557-1562. http://dx.doi.org/:10.1016/s0264-410x(01)00493
19. Fan W., Zhang M., Zhu Y.M., at al. Immunogenicity of Hepatitis B Vaccine in Preterm or Low Birth Weight Infants: A Meta-Analysis. Am J Prev Med. 2020; 59(2): 278-287. http://dx.doi.org/10.1016/j.amepre.2020.03.009
20. Fan W., Zhang M., Zhu Y., at al Immunogenicity of Hepatitis B Vaccine in Preterm or Low Birth Weight Infants: A Meta-Analysis. American Journal of Preventive Medicine. 2020; 59 (5): 278-287 doi.org/10.1016/j.amepre.2020.03.009
21. Belloni C., Chirico G., Pistorio A., at al. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta. Paediatr. 1998; 87(3): 336-8 http://dx.doi.org/10.1080/08035259850157426. PMID: 9560044
22. Lei D., Miller T., Carr, J. Buttery, J. at al. Timing of the First Dose of the Hepatitis B Vaccine in Preterm Infants. Vaccines/ 2022; (10): 1656. https://doi.org/10.3390/vaccines10101656
23. Omeñaca F., Garcia-Sicilia J., García-Corbeira P., at al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005; 116(6): 1292-8. http://dx.doi.org/10.1542/peds.2004-2336
24. Martinón-Torres F., Czajka H., Center K.J., at al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics. 2015; 135(4): 876-86. http://dx.doi.org/10.1542/peds.2014-2941
25. Martinón-Torres F., Wysocki J., Center K.J., at al. Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants. Pediatr Infect Dis J. 2017; 36 (3): 326-332. http://dx.doi.org/10.1097/INF.0000000000001428
26. Shinefield H., Black S., Ray P., at al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. The Pediatric Infectious Disease Journal. 2002; 21(3):p 182-186 http://dx.doi.org/10.1097/00006454-200203000-00003
27. Dennehy P.H. Cortese M.M., Bégué, R.E., et al. A Case-Control Study to Determine Risk Factors for Hospitalization for Rotavirus Gastroenteritis in U.S. Children. The Pediatric Infectious Disease Journal. 2006; 25(12): 1123-1131 http://dx.doi.org/10.1097/01.inf.0000243777.01375.5b
28. Vazquez L., Garcia F., Ruttimann R., at al. Immunogenicity and reactogenicity of DIPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr. 2008; 97 (9): 1243-1249 http://dx.doi.org/10.1111/j.1651-2227.2008.00884.x
29. Kulkarni-Munje A., Malshe N., Palkar S., at al. Immune Response of Indian Preterm Infants to Pentavalent Vaccine Varies With Component Antigens and Gestational Age. Front Immunol. 2021; 12: 592-731. http://dx.doi.org/10.3389/fimmu.2021.592731
30. Chiappini E., Petrolini C., Sandini E., et al. Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology. Expert Rev. Vaccines. 2019; 18 (5): 523–545. http://dx.doi.org/10.1080/14760584.2019.1604230
31. Leineweber B., Grote V., Schaad U.B., at al. Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicellazoster virus in preterm and full term newborns. Pediatr Infect Dis J 2004; 23: 361-363 http://dx.doi.org/10.1097/00006454-200404000-00019
32. Leuridan E., Hens N., Hutse V., at al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ. 2010; 340: 1626; http://dx.doi.org/10.1136/bmj.c1626
33. Pinquier D., Gagneur A., Aubert M., at al. Distribution of serum measles-neutralizing antibodies according to age in women of childbearing age in France in 2005-2006: impact of routine immunization. Pediatr Infect Dis J. 2007; 26: 749-50; http://dx.doi.org/10.1097/INF.0b013e31806211aa
34. Griffin M.P., Yuan Y., Takas T. Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020; 383(5): 415-425 http://dx.doi.org/10.1056/NEJMoa1913556
35. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The Impact-RSV Study Group. Pediatrics. 1998; 102(3 Pt 1): 531-537
36. Pfister R.E., Aeschbach V., Niksic-Stuber V., at al. Safety of DTaP-based combined immunization in very-low-birthweight premature infants: frequent but mostly benign cardiorespiratory events. J Pediatr. 2004; 145: 58–66. http://dx.doi.org/10.1016/j.jpeds.2004.04.006
37. Bohnhorst B., Weidlich C., Peter C., at al. Cardiorespiratory Events Following the Second Routine Immunization in Preterm Infants: Risk Assessment and Monitoring Recommendations. Vaccines (Basel). 2021; 9(8): 909. http://dx.doi.org/10.3390/vaccines9080909. PMID: 34452034
38. Florinskaja E.B., Keshishjan E.S. Vakcinacija nedonoshennyh detei. Rossijskij vestnik perinatologii i pediatrii. 2021; 66:(6): 6–16. http://dx.doi.org/10.21508/1027–4065–2021–66–6–6–16
39. Sebghati M., Khalil A. Uptake of vaccination in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2021;76: 53-65. http://dx.doi.org/10.1016/j.bpobgyn.2021.03.007
40. WHO prequalified vaccines. ROTASIIL Liquid. Geneva: World Health Organization https://extranet.who.int/pqweb/content/rotasiil-liquid, accessed June 2021)
41. United Nations Children’s Fund and World Health Organization. Low Birthweight: country, regional and global estimates. New York (USA): UNICEF; 2004. https://apps.who.int/iris/bitstream/handle/10665/43184/9280638327.pdf?sequence=1&isAllowed=y
42. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women – Advisory Committee on Immunization Practices (ACIP), 2012. MMWR. 2013; 62 (07): 131-135.
43. Maltezou HC, Rodolakis A. Vaccination of pregnant women against influenza: what is the optimal timing? Hum Vaccin Immunother. 2021; 17(8): 2723-2727. http://dx.doi.org/10.1080/21645515.2021.1889934
Review
For citations:
Ruleva A.A., Kharit S.M. Vaccination of premature newborns. Journal Infectology. 2023;15(4):25-34. (In Russ.) https://doi.org/10.22625/2072-6732-2023-15-4-25-34
Views:
626
.png)
.png)
Email this article 